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Chronic valve disease (CVD) is the most common clinically significant heart disease of dogs, 
affecting 20 to 40% of dogs. The aim of this study was to evaluate the serum protein profile of 
healthy and CVD affected dogs, by means of an isobaric tandem mass tag (TMT) label-based 
high-resolution quantitative proteomic approach. Additionally, conventional cardiac biomarkers 
were measured in the serum, functional bioinformatics analysis was employed for elucidating 
molecular mechanisms and pathways associated with CVD, and validation of proteomic results 
was performed by immunoassays and Western blotting. Of 290 identified and quantified 
proteins, 15 proteins showed significantly different abundances (p<0.05), including 
antithrombin-III, alpha-2-antiplasmin, tetranectin, apolipoprotein M, adiponectin, inter-alpha-
trypsin inhibitor heavy chain H1, gelsolin and apolipoprotein B-100. The identified proteins with 
differently abundances are involved in a number of pathways, such as complement and 
coagulation cascades, haemostasis, regulation of actin cytoskeleton, lipid metabolism and 
transport. We found comparative similarities with human disease in terms of identified proteins 
and GO pathways, which confirmed similar pathophysiology of this disease, but also differences, 
mainly in lipid metabolism.
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Significance 
There have been few investigations of canine serum proteome despite the potential for biomarker 
discovery and comparative disease analysis. Establishing serum proteomic signatures in healthy 
dogs and dogs with CVD will benefit for understanding the aetiology of disease in dogs, identify 
putative biomarkers and provide models of comparative human disease. Circulating biomarkers 
are important for understanding of the mechanisms of cardiovascular disease and high incidence 
of CVD in dogs prioritizes the search for novel biomarkers.  
 
Highlights 
• Establishing serum proteomic signatures in healthy dogs and dogs with CVD 
• TMT-based relative quantification revealed 15 proteins with significantly lower 
differential abundances in dogs with CVD 
• Proteins validated with immunoassays confirmed consistence with proteomic results 
• Serum proteins involved in extracellular structure organization, haemostasis pathway and 

















1. Introduction  
 
      Veterinary proteomics is an evolving field which holds great promise not only for 
fundamental and applied discoveries regarding biology and pathology of domestic species, but 
can also be implemented in comparative applications of human diseases research [1].  The heart 
in dogs and humans is similar in many characteristics on both the organ and cellular levels. 
Canine heart rate, body weight, and heart weight are more comparable to humans than the other 
animals such as mice, rabbits, and rats. The opportunity to use dog as model animal for 
comparative disease studies is based on the sequencing of the canine genome and the increasing 
availability of canine specific biological tools and reagents [2]. Chronic valve disease (CVD) is 
the most common heart disease in dogs and the most frequent cause of congestive heart failure in 
this species, representing approximately 75% of all heart disease in the dog [3]. CVD is 
pathologically identical in humans and dogs, suggesting a common pathogenesis in these species, 
and creating an increasing interest in the canine CVD as a model for the human medicine. 
Various other names for the disease are used and include endocardiosis, valvular regurgitation, 
valvular insufficiency, mitral regurgitation, myxomatous degeneration of the valve, degenerative 
mitral valve disease, senile nodular sclerosis, mucoid degeneration, chronic mitral valve fibrosis 
[4]. 
Disease is characterised by a chronic progression, from mild, clinically silent disease to 
severe disease with signs of congestive heart failure. Myxomatous valvular degeneration  most 
often leads to lesions of the mitral valve (62% of cases), sometimes both atrioventricular valves 
(33% of cases) and infrequently the tricuspid valve (1% of cases) [5] .  
Reported risk factors associated with progression of disease or death in dogs with CVD 
include age, gender, intensity of heart murmur, degree of valve prolapse, severity of valve 
lesions, the degree of mitral valve regurgitation, degree of left atrial enlargement, severity of 
eccentric hypertrophy, rupture of chordae tendinae and increased concentration of natriuretic 
peptides. The vast majority of the breeds at elevated risk of CVD are small or toy breeds, males 
are 1.5 times more represented than females, and the disease is rare before the age of 4 years [3, 
4, 6]. 
The aim of this study was to evaluate the serum protein profile of healthy and CVD affected 
dogs, by means of an isobaric tandem mass tag (TMT) label-based high-resolution quantitative 
proteomic approach. Additionally, conventional cardiac biomarkers were measured in the serum, 
functional bioinformatics analysis was employed for elucidating molecular mechanisms and 
pathways associated with CVD, and validation of proteomic results was performed by 
immunoassays and Western blotting. Only one previous study has been performed to identify 
serum proteins that were differentially expressed in healthy Cavalier King Charles Spaniel and 
those affected by CVD in mild to severe stages, using two-dimensional gel electrophoresis 
separation and analysis by MALDI-TOF-MS for protein identification [7]. To the authors´ 
knowledge, this is the first proteomic study of serum of dogs with CVD, where label-based 
quantitative LC-MS/MS approach was used. 
 
2. Materials and methods 
2.1 Animals  
      Two groups of dogs were enrolled in the study in the period between June 2015 and May 
2017: 8 clinically healthy dogs (used as controls) and 8 dogs diagnosed with CVD. The study 
was approved by the Committee on the Ethics of the University of Zagreb, Faculty of Veterinary 
Medicine (Permit Number: 640–01/14–305/16, 251–61-01/139–14-28). Healthy dogs were 
admitted to the Clinic for Internal Diseases, Faculty of Veterinary Medicine, University of 
Zagreb, Croatia, while diseased dogs were admitted to the Small Animals Clinic, Department of 
Clinical Veterinary Science, Vetsuisse Faculty, University of Bern, Switzerland. Serum of dogs 
with CVD was collected at the time of initial diagnosis and before any treatment. 
      All dogs of the control group underwent clinical examination, haematological and 
biochemical serum analyses, as well as cardiac function evaluation performed in unsedated dogs, 
which included a 1-min 6 lead ECG (ASPEL, AsCard Mr. Silver) and transthoracic 
echocardiography using Esaote MyLab40 Vet machine and a 5 MHz sector transducer. Dogs 
were diagnosed with CVD-MV if the history, clinical exam results and the results of an 
ultrasound imaging were confirmative and other acquired heart disease so as congenital heart 
diseases were ruled out [8]. The cardiac evaluation of dogs included physical examination, 
thoracic radiographs evaluated by a board-certified radiologist, a 1-min 6 lead ECG (Schiller AT 
101) and transthoracic echocardiography performed by a board certified cardiologist (AK). 
Echocardiography was performed using an Aloka ProSound Alpha 5SV machine and a 5-MHz 
sector transducer in unsedated dogs. Echocardiography was performed in a standard manner [8]. 
Diseased dogs were classified according to the American College of Veterinary Internal 
Medicine (ACVIM) consensus guidelines for the diagnosis and treatment of myxomatous mitral 
valve disease in dogs [9]. 
      All procedures were conducted in accordance with EU Directive 2010/63/EU for animal 
experiments, as well as subject to informed owner consent. 
      Serum was obtained from all dogs by centrifugation of completely clotted blood at 3500g for 
10 min at room temperature. Supernatants were collected, aliquoted and stored at −80 °C until 
analyses. All samples used for repetitive analysis were frozen in aliquots and only vials needed 
for each assay run were used, to avoid possible changes caused by repetitive thawing and 
freezing. 
 
2.2 Serum biochemistry and cardiac biomarker analyses 
      One serum aliquot was used for measurement of biochemical parameters using commercial 
reagents (Beckman Coulter) per manufacturer's instructions in an automatic analyser (Olympus 
AU 640, Hamburg, Germany). The following parameters were measured: serum urea, creatinine, 
bilirubin, glucose, proteins, albumin, aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), gamma-glutamyl transferase (GGT), alkaline phosphatase (AP), creatine kinase (CPK), 
lactate dehydrogenase (LDH), C-reactive protein (CRP), alpha-amylase, lipase, cholesterol, 
triglycerides, calcium, phosphates. 
      Cardiac troponin I (cTnI) was measured using a commercially available ADVIA Centaur 
TnI-Ultra assay, which is a high-sensitivity immunoassay validated for use in both humans and 
dogs [10]. Analysis was performed in Dubrava Clinical Hospital, Department of clinical 
diagnostics (Zagreb, Croatia) using Siemens Advia Centaur XP according to manufacturer's 
instructions. Samples which had serum concentration of cTnI below the lower level of detection 
of the assay were allocated a value of 0.01 μg/L. Analysis of N-terminal pro b-type natriuretic 
peptide (NT-proBNP) concentration in all samples was performed in Vet Med Labor GmbH, 
reference IDEXX Laboratory (Germany) using IDEXX Cardiopet® proBNP test. 
 
2.3 Proteomic analysis by LC-MS/MS 
 
      Proteomic analysis of canine serum samples was performed by TMT-based quantitative 
approach as described previously [11]. In brief, after total protein concentration determination 
using Bradford assay (Thermo Scientific, Rockford, USA), 35 μg of total proteins from samples 
and internal standard (a pool of equal protein amount from all samples used as a reference for 
normalization) were diluted to a volume of 50 μL using 0.1 M triethyl ammonium bicarbonate 
(TEAB, Thermo Scientific, Rockford, USA), reduced by adding 2.5 μL of 200 mM DTT (60 
min, 55 °C) (Sigma Aldrich, St. Louis, MO, USA), alkylated by adding 2.5 μL of 375 mM IAA 
(30 min, room temperature in the dark) (Sigma Aldrich, St. Lois, MO, USA) and acetone-
precipitated (addition of 300 μL, overnight, −20 °C). Protein pellets were collected subsequently 
by centrifugation (9000g, 4 °C), dissolved in 50 μL of 0.1 M TEAB and digested using 1 μL of 
trypsin (1 mg/mL, Promega; trypsin-to-protein ratio 1:35, at 37 °C overnight). 
      TMT sixplex reagents (Thermo Scientific, Rockford, IL, USA) were prepared according to 
the manufacturer's procedure and 19 μL of the appropriate TMT label was added to each sample 
used for the labelling reaction (60 min, room temperature) which was quenched by 5% 
hydroxylamine (Sigma-Aldrich, St. Louis, MO, USA). Five TMT-modified peptide samples 
were combined with the internal standard (labeled with TMT m/z 126) into the new tube, 
aliquoted, dried and stored at −20 °C for further analysis. A total of 16 samples led to 4 
individual TMT experiments with the inclusion of internal standards in each experiment but 2 
samples were repeated using the same internal standard because of low labelling efficiency. 
      High resolution LC-MS/MS analysis of TMT-labelled peptides was carried out using an 
Ultimate 3000 RSLCnano system (Dionex, Germering, Germany) coupled to a Q Exactive Plus 
mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Peptides were dissolved in 
loading solvent (1% ACN, 0.1% formic acid) and loaded onto the trap column (C18 PepMap100, 
5 μm, 100A, 300 μm×5 mm), desalted for 12 min at the flow rate of 15 μL/min and separated on 
the analytical column (PepMap™ RSLC C18, 50 cm×75 μm) using a linear gradient of 5–45% 
mobile phase B (0.1% formic acid in 80% ACN) over 120 min, 45% to 90% for 2 min, held at 
80% for 2 min and re-equilibrated at 5% B for 20 min at the flow rate of 300 nL/min. Mobile 
phase A consisted of 0.1% formic acid in water. Ionisation was achieved using nanospray Flex 
ion source (Thermo Fisher Scientific, Bremen, Germany) containing a 10 μm-inner diameter 
SilicaTip emitter (New Objective, USA). The MS operated in positive ion mode using DDA 
Top8 method. Full scan MS spectra were acquired in range from m/z 350.0 to m/z 1800.0 with a 
resolution of 70,000, 110 ms injection time, AGC target 1×106, a ± 2.0 Da isolation window and 
the dynamic exclusion 30 s. HCD fragmentation was performed at step collision energy (29% 
and 35% NCE) with a resolution of 17,500 and AGC target of 2×105. Precursor ions with 
unassigned charge state, as well as charge states of +1 and more than +7 were excluded from 
fragmentation. 
      Acquired MS/MS spectra were analysed for protein identification and quantification using 
the SEQUEST algorithm implemented into Proteome Discoverer (version 2.0., ThermoFisher 
Scientific). Database search against Canis lupus FASTA files (downloaded from NCBI database 
on 14/10/2016, 41787 sequences) was performed according to the following parameters: two 
trypsin missed cleavage sites, precursor and fragment mass tolerances of 10 ppm and 0.02 Da, 
respectively; carbamidomethyl (C) fixed peptide modification, oxidation (M), deamidation (N,Q) 
and TMT sixplex (K, peptide N-terminus) dynamic modifications. The false discovery rate 
(FDR) for peptide identification was calculated using the Percolator algorithm in the Proteome 
Discoverer workflow based on the search results against a decoy database and was set at 1% 
FDR. At least two unique peptides and 5% FDR were required for reporting confidently 
identified proteins.  
      Protein quantification was accomplished by correlating the relative intensities of reporter 
ions extracted from tandem mass spectra to that of the peptides selected for MS/MS 
fragmentation.  The internal standard was used to compare relative quantification results for each 
protein between the experiments (sixplexes).  
      The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE partner repository with the dataset identifier PXD017129. 
2.4 Bioinformatic analysis 
      Proteins with significantly differential abundances observed by proteomic analyses were 
further functionally analysed using bioinformatics tools. As the human database is more 
complete than the canine one (reviewed proteins in UniprotKB/Swiss-prot release 2018_01: 
humans 20,259, dogs 817), dog's proteins were converted to converted to human gene official 
names by the database bioDBnet. The 10 unique proteins have been enriched for their best 
interacting proteins according to Intact and Reactome databases, using the tool CluePedia 
(v1.5.2) from Cytoscape (v3.6.1). Maximum number of 10 best interactors has been set. 
      The resulting interactome was used to determine the enriched GO terms, using ClueGO 
(v2.5.2) from cytoscape with GO_biologicalprocess (04.09.2018), GO levels from 3 to 12, 
minimal number of gene = 2, mimimum percentage = 3.0, Kappa score theshold = 0.4, evidence 
codes used All_without_IEA.  
      List of GO terms was then submitted to analysis by ReviGO to remove redundant terms and 
define GO groups based on similarity, with the SimRel semantic similarity measure. Redundant 
GO terms were then removed from the interactome, realized with Cytoscape. GOterms with a 
minimum of 2 initial proteins have been considered for the analysis of GO terms related with 
CVD. Interactome have been designed using the radial layout of Cytoscape. 
 
2.5 Validation of proteomic results 
 
      Validation of proteomics results was performed by ELISA and Western blotting using the 
serum samples of the same patients as in proteomic analysis. All samples used for repetitive 
analysis were frozen in aliquots and only vials needed for each assay run were used, to avoid 
possible changes caused by repetitive thawing and freezing. 
      Canine specific ELISA kits were used for apoB-100 (BlueGene Biotech, Shanghai, China), 
apoD (ABclonal, Woburn, USA) and adiponectin (Wuhan Fine Biotech Co., LTD., Wuhan, 
China) according to manufacturer’s instructions. For analytical performance of the ELISA 
assays, assay precision and accuracy were calculated [12, 13]. For intra-assay precision, pool of 
samples with different concentrations of analytes were prepared from serum, while for inter-
assay precision, pool was divided into aliquots and stored in plastic vials at −20 °C until analysis. 
Intra-assay coefficient of variation (CV) was calculated after analysis of pool six times in a 
single assay run. Inter-assay CV was determined by analysing the same samples in five separate 
runs carried out on different days. The accuracy of the assays was evaluated indirectly by 
linearity under dilution. Briefly, serum pool was serially diluted with diluent provided with the 
kit and analysed.  
 
      For immunoblotting, the samples (30 μg of total protein) were boiled for 3 min at 95 0C in 
Laemmli SDS loading buffer and loaded on 10% SDS polyacrylamide gel and after 
electrophoresis (1 h at 110 V) transferred to a PVDF membrane (Amersham Hybond, 0.45 
PVDF, GE Healthcare Lifescience) (2 h at 65 V, 150 mA) in 20% methanol (Sigma) transfer 
buffer at 4 °C using Biostep electro blotting module. The membranes were blocked for 1 h at 
room temperature with shaking in blocking buffer (1xTris buffered saline (TBS)/0,1% Tween 
20/0,2% I-Block reagent). Subsequently, the membrane was incubated at 4 ºC with primary 
antibody for adiponectin (1:500 in blocking buffer; from Santa Cruz Biotechnology, Heildeberg, 
Germany) and kininogen-1 (1:500 in blocking buffer; Antibodies-online GmbH, Achen, 
Germany). Membranes were then washed three times with TBST buffer and incubated with 
secondary antibody (rabbit anti-mouse from Santa Cruz Biotechnology, 1:2000). Proteins were 
visualized by chemiluminescence using HRP chemiluminescence blotting substrate (Radiance 
Plus, Azure Biosystems, USA) on Odyssey Fc (LI-COR, Bad Homburg, Germany). The 
abundance of the protein of interest was normalized to the total amount of protein in each lane 
after staining with Ponceau S. Western blots were quantified using ImageJ software (National 
Institutes of Health). Statistical validation of the data was achieved by Mann-Whitney test, with 
P value < 0.05 considered statistically significant. 
 
2.6 Statistical analysis 
 
For proteomics, statistical analysis was performed using using R (v3.4.3) under the RStudio 
environment (v1.0.143) [14, 15]. Paired t-test was applied to calculate p-values to determine 
statistical significance among healthy dogs and dogs with CVD. For immunoblotting, statistical 
analysis was performed using the statistical software, GraphPad Prism 5 (GraphPad Software 
Inc., San Diego, CA). Differences between healthy and diseased dogs were assessed by Mann-
Whitney test. Non-parametric statistics was chosen due to the small sample size. P-value < 0.05 





3. Results  
3.1 Animals and heart function 
      The control group consisted of 6 females (1 spayed) and 2 males, aged between 3 and 10 
years, of following breeds: 2 Miniature Schnauzers, Dachshund, Maltese, Border collie and 3 
mixed-breed dogs. In the group of dogs diagnosed with CVD there were 3 females (all spayed) 
and 5 males (of which 3 castrated), aged between 8 and 12 years. These were dogs of 7 different 
breeds (2 Cavalier King Charles Spaniels, Australian Kelpie, Coton de Tuléar, Borzoi, Miniature 
Schnauzer, Toy Australian Shepherd and Doberman). At initial physical examination all dogs of 
CVD group were considered in heart failure based on elevated respiratory rate and effort, signs 
of interstitial or interstitial-alveolar lung pattern and absolutely dilated pulmonic veins on the 
thoracic radiographs. All were classified as ACVIM class C. Six dogs were in sinus rhythm. Two 
of those dogs had rare ventricular premature complexes and one dog rare supraventricular 
premature beats.  Two dogs showed atrial fibrillation with a ventricular rate 190-250/min. Seven 
of the eight dogs also had a tricuspid endocardiosis, four of which had signs of mild to moderate 
pulmonary hypertension. Two out of eight dogs showed a slight regurgitation on the aortic valve 
and pulmonary valves (Supplemental data 1).  
 
3.2 Serum biochemistry and cardiac biomarkers 
        Values of serum biochemical parameters are presented in Table 1. as median and 
interquartile range, together with P value for comparisons of groups. Concentrations of urea, 
creatinine, total proteins, CRP, Ca, phosphates and cholesterol, as well as activities of ALT, AP 
and LDH were significantly higher in serum of dogs with CVD compared to healthy dogs. 
Cardiac biomarkers, cTnI and NT-proBNP, also had significantly higher concentrations in dogs 







Table  1. Serum biochemical parameters measured in serum of dogs with CVD and healthy dogs. 
AST - aspartate aminotransferase, ALT - alanine aminotransferase, GGT - gamma-glutamyl 
transferase, AP - alkaline phosphatase, CPK - creatine kinase, LDH - lactate dehydrogenase, 
CRP C-reactive protein, cTnI - cardiac troponin I, N-terminal pro b-type natriuretic peptide - 
NT-proBNP. 
Parameter (unit) Healthy dogs 
(median(Q1-Q3) 
Dogs with CVD 
(median(Q1-Q3) 
P value 
Urea (mmol/L) 5.55 (4.98 - 7.40) 17.05 (12.68 - 34.78) 0.003 
Creatinine ( mol/L) 82 (61.5 - 85.75) 113.5 (86.25 - 144) 0.008 
Total protein (g/L) 59.5 (58.25 - 65.75) 74 (66 - 91) 0.007 
Albumin (g/L) 32.5 (29.75 - 35) 34.50 (34 - 43.5) 0.112 
Bilirubin ( mol/L) 3.05 (2.93 - 3.55) 3.3 (1.95 - 5.28) 0.650 
Glucose (mmol/L) 5.65 (5.33 - 5.8) 6.65 (4.98 - 8.18) 0.372 
AST (U/L) 23 (21.5 - 32.25) 41.50 (25.5 - 76.75) 0.091 
ALT (U/L) 42.5 (22 - 54.75) 84 (54.5 - 129.5) 0.031 
GGT (U/L) 3.5 (3 - 4.75) 2.5 (1.75 - 7.25) 0.694 
AP (U/L) 29.5 (24.5 - 46) 198.5 (74.25 - 320) < 0.001 
CPK (U/L) 104 (81.75 - 134.3) 164.5 (99.5 - 391.5) 0.161 
Alpha amylase (U/L) 599 (362.3 - 691) 614.5 (440.3 - 1079) 0.279 
Lipase (U/L) 272.5 (146.5 - 534.8) 480 (389.3 - 631.8) 0.065 
LDH (U/L) 59 (47 - 74.75) 217.5 (161.8 - 361.8) 0.001 
CRP (mg/L) 0.6 (0.05 - 6.1) 23.2 (9.15 - 44.05) 0.006 
Calcium (mmol/L) 2.55 (2.5 - 2.6) 2.84 (2.66 - 3.15) 0.007 
Phosphates (mmol/L) 1.4 (1.2 - 1.48) 2.1 (1.72 - 2.45) 0.013 
Triglycerides (mmol/L) 0.65 (0.53 - 0.78) 1.3 (1.03 - 1.65) 0.005 
Cholesterol (mmol/L) 6.85 (5.38 - 8.65) 10.6 (9.75 - 12.8) 0.021 
cTnI (μg/L) 0.01 (0.01 - 0.028) 1.32 (0.11 - 4.52) < 0.001 




        In this study, 290 quantifiable proteins (171 of which were master proteins and 47 master 
protein candidates, respectively) were identified by label-based quantitative proteomic approach 
according to set criteria (2 unique peptides and 5% FDR) (Supplemental data 2). In total, there 
were 15 proteins with significantly differential abundances between healthy and dogs with CVD, 
and all of them were downregulated in diseased dogs (Table 2).   
Table 2. Proteins with significantly differential abundances between healthy and dogs with CVD 
identified and quantified using TMT approach. 
Accession 
numbera 





359320010 antithrombin-III 0.04 -0.56 















928162811 tetranectinb 0.02 -0.73 
928151046 apolipoprotein M 
isoform X2b 
0.02 -0.65 














like isoform X1b 
0.02 -0.62 
aAccession number from NCBI protein database for Canis lupus familiaris. 
bproteins predicted in Canis lupus familiaris, with no evidence of existence to date at protein, 
transcript or homology levels 
 
3.4 Bioinformatics  
 
       Proteins with significantly differential abundances were used as a starting point for creating 
protein interacting networks using different softwares. An additional 77 associated proteins have 
been added to the initial proteins by the enrichment step. From the 87 genes (initial proteins + 
enriched), 46 (54.8%) were associated to a GO term. Nine of the 10 (90%) initial proteins have 
been associated with a GO term. Only ITIH1 was not associated with a GO term. In total, 32 GO 
terms have been identified, forming 13 groups.  
 








wound healing 17 4 6.94 
extracellular structure organization 16 3 8.25 
negative regulation of response to external 
stimulus 12 4 6.26 
organic hydroxy compound transport 9 3 3.74 
regulation of plasma lipoprotein particle levels 8 3 5.19 
positive regulation of lipid metabolic process 8 2 4.30 
lipid homeostasis 7 2 3.73 
retinoid metabolic process 6 2 3.21 
plasminogen activation 5 3 4.96 
cholesterol homeostasis 5 2 2.58 
regulation of smooth muscle cell proliferation 5 3 2.14 
renal protein absorption 2 2 2.12 
 
 
After refinement, 12 representative GO terms have been selected (Table 3, Figure 1). 
Adiponectin (identified initially by proteomics) was associated with multiple GO terms. GO 
terms extracellular structure organization and wound healing seems to be essential in this 
disease. Lipid metabolism and transport are also important, as they are present with different 
related GO terms like lipid homeostasis, cholesterol homeostasis, regulation of plasma 




3.5 Validation of proteomic results 
       In order to verify differences in serum protein abundances observed by proteomic analysis, 
selected proteins were validated by ELISA assays and Western blotting. All ELISA assays 
evaluated in the present study showed adequate precision with intra- and inter-assay CVs lower 
than 15%, the limit of the objective analytic performance standard for precision [16]. For 
accuracy of the assays linearity under dilution was accomplished by ordinary linear regression 
analysis comparing the measured concentrations of analyte with the expected levels. Dilution of 
canine serum samples with different analyte concentrations resulted in linear regression 
equations with correlation coefficient close to 1.0 (r > 0.98 for all assays). 
      All tested markers, apolipoprotein B-100, apolipoprotein D and adiponectin, showed 
significant differences between dogs with CVD and healthy dogs (Figure 2). Adiponectin 
concentration was significantly lower in serum of dogs with CVD (median, interquartile range: 
489.4 ng/mL, 311.5 – 859.1 ng/mL) compared to healthy dogs (1887 ng/mL, 769.9 – 2179 
ng/mL; P = 0.002), as well as apoB-100 concentration in dogs with CVD (2.9 g/mL, 2.3 – 5.3 
g/mL) compared to healthy dogs (5.6 g/mL, 5.2 – 6.8 g/mL; P = 0.026) and apoD 
concentration in dogs with CVD (608.1 pg/mL, 487 – 978.1 pg/mL) compared to healthy dogs 
(1108 pg/mL, 822.9 – 2257 pg/mL; P = 0.050). In total, all proteins validated with 
immunoassays confirmed consistence with proteomic results.  
      Two selected proteins, adiponectin and kininogen-1, were validated by Western blotting 
using total protein load after Ponceau S staining as a normalisation reference. The relative 
abundance of ADPN was significantly lower in serum of dogs with CVD compared to healthy 
dogs (P = 0.005), while for kininogen-1 there was no statistical significance (data not shown). 
We were not able to confirm kininogen-1 consistence with proteomic data, possibly due to the 
existence of different KIN1 isoforms in serum. 
4. Discussion  
Using TMT label-based relative quantification proteomics approach, we have found 15 
differentially abundant serum proteins between dogs with CVD and healthy dogs. The identified 
proteins with differently abundances are involved in a number of pathways, such as complement 
and coagulation cascades, haemostasis, regulation of actin cytoskeleton, lipid metabolism and 
transport.  
One previous study in Cavalier King Charles Spaniel using two-dimensional gel 
electrophoresis separation and analysis by MALDI-TOF-MS for protein identification identified 
eight proteins differentially expressed among healthy and dogs with CVD [7]. None of those 
proteins were identified as differentially abundant in this study, probably due to difference in 
proteomic approach. However, there are similarities with research in humans, with special 
emphasis to tetranectin and gelsolin as novel biomarkers of cardiovascular disease. Other 
identified proteins are also consistent to similar studies in human medicine, with exception of 
apolipoproteins which showed different trend. 
One of the proteins we found differentially expressed in CVD dogs was adiponectin, a major 
adipocyte-secreted protein (adipokine), a key component that mediates the cross-talk between 
adipose tissue, cardiac cells and the vasculature. Several studies in humans and rodents showed 
that adipokines affect cardiovascular functions, as well as many other physiological processes 
including regulation of energy metabolism, immune function, and inflammation [17]. In a recent 
study adiponectin concentrations were found significantly lower in dogs with CVD [18], while in 
another study increased adiponectin concentration was found in dogs with dilated 
cardiomyopathy compared to healthy dogs and to dogs with CVD in dogs [19]. Identification of 
mRNAs encoding both adiponectin receptors in cardiac tissues of dogs confirms that circulating 
adiponectin directly affects cardiomyocytes in dogs with CVD [19]. 
High adiponectin concentrations in healthy humans are associated with low cardiovascular 
risk and adiponectin concentration is associated with slowing the progression of cardiovascular 
diseases such as cardiac hypertrophy, ischemic injury, and atherosclerosis in humans [20, 21].  
In our study we found lower abundances of this protein in dogs with CVD compared to 
controls, confirmed with both, immunoassay and immunoblotting, validation method, suggesting 
its role in modulating cardiovascular function by acting with an anti-inflammmatory effect, 
reducing oxidative stress and promoting endothelial repair during vascular dysfunction. 
Another identified protein is part of the inter-alpha-trypsin inhibitors (ITI) family of plasma 
serine protease inhibitors, composed of a light chain – bikunin, and homologous heavy chains, 
contributing to extracellular matrix stability by covalent linkage to hyaluronan. So far, inter-
alpha-trypsin inhibitor heavy chain H1 (ITIH) molecules have been shown to play a particularly 
important role in inflammation and carcinogenesis, and have been demonstrated to be both 
positive and negative acute phase proteins under various conditions [22]. In our study, lower 
protein abundances were found in CVD group. The most consistent histopathologic finding in 
CVD is accumulation of glycosaminoglycans, mainly hyaluronic acid, in the extracellular matrix 
of the mitral valve [23, 24]. Decrease of ITIH1 could be due to the impairment of extracellular 
matrix stabilization in cardiac tissue of diseased dogs. Additionally, reduced ITIH1 levels in the 
serum may contribute to reduced protease inhibitor activity and excess protease-mediated tissue 
injury in CVD group. This is also suggestive of an inflammatory component underlying this 
disease, as rapid consumption of protease inhibitors, such as ITIH1, are evidenced in 
pathophysiology of inflammation in order to prevent excess activation of proteases and limit the 
potential injurious actions of protease activation on endothelial and epithelial tissues [25]. 
Gelsolin, the actin-scavenging protein, had lower protein abundances in CVD group 
compared to controls. Actins are released into the systemic circulation after disruption of the cell 
membrane as a result of necrosis. The release of actin into the systemic circulation in response to 
injury or illness-associated necrosis results in adverse pathophysiologic consequences including 
increase of blood viscosity and disturbances in microvascular flow, activation of platelets with 
resulting platelet aggregation, and microvascular thrombosis, all contributing to tissue injury due 
to the high toxicity of actin [26]. In a majority of diseases, decline of gelsolin precedes, and 
therefore might predict, tissue and organ injury, and can be a predictor of critical care 
complications; and these alterations are primarily associated with actin scavenging and anti-
inflammatory features of gelsolin. A compelling number of animal studies also demonstrate a 
broad spectrum of beneficial effects mediated by gelsolin, suggesting therapeutic utility for 
extracellular recombinant gelsolin [26]. Similar mechanism of this actin-scavenging protein 
could be proposed in canine CVD, due to lower protein abundances found in dogs with CVD. 
Cardiovascular diseases are associated with alteration of haemostasis. We found lower 
protein abundances of antithrombin III (AT III), alpha-2-antiplasmin, tetranectin and kininogen-1 
in dogs affected with CVD compared to healthy dogs. 
In humans, low antithrombin is established risk factor for thrombosis and the risk of cardiac 
events was positively correlated to fibrinogen and negatively correlated to antithrombin III 
activity measurements [27]. In previous studies of canine CVD leading to congestive heart 
failure (CHF), AT III were decreased in dogs with CVD [28]. Natural anticoagulant mechanisms 
are amplified to prevent excessive thrombin generation. AT III, as part of the most important 
anticoagulant pathway, inhibit fibrinogen conversion into plasmin by creating thrombin-
antithrombin complexes. Low AT III levels are caused by excessive thrombin generation and 
thereby increased consumption of the inhibitor leads to hypercoagulability in CVD. 
Alpha-2-antiplasmin is a major inhibitor and regulator of fibrinolysis and one of the essential 
factors involved in haemostasis. It is a member of the serine proteinase inhibitor (serpin) family 
and inhibits proteases in general, including trypsin, chymotrypsin, plasma kallikrein, but its main 
physiological activity is very rapid inhibition of plasmin by forming a stable complex with this 
proteinase [29]. Lower protein abundances of alpha-2-antiplasmin found in CVD group may 
suggest fibrinolysis inhibitors consumption and increased fibrinolytic activity due to 
hypercoagulable state present in disease. Reported alterations in haematologic parameters would 
shift an overall haemostatic balance toward a more hypercoagulable state in the dogs with CVD. 
Another regulator of fibrinolysis, tetranectin, was found to be decreased in our study in dogs 
with CVD compared to controls. Tetranectin is a C-type lectin and an adhesion molecule found 
on endothelial cells and platelets that specifically binds to the plasminogen kringle 4 domain, 
thereby enhancing plasminogen activation and inhibits the proliferation of endothelial cells [30]. 
A recent proteomics study discovered that the serum level of tetranectin was among the 
predictors of atherosclerotic cardiovascular disease after adjusting for established risk factors, 
with tetranectin levels inversely correlated with the risk of atherosclerotic cardiovascular 
disease [31]. Population studies have shown that decreased plasma tetranectin levels are also 
associated with coronary artery disease [32] and acute myocardial infarction [33]. These studies 
in humans are in agreement with the result obtained in this research, suggesting that changes of 
coagulation and fibrinolysis system play a vital role in pathophysiology of CVD. It is possible 
that the downregulation of tetranectin is due to its fibrinolytic property in thrombus 
breakdown. 
Kininogen-1, component of a coagulation system, is the precursor protein to high-molecular-
weight kininogen (HMWK), low-molecular-weight kininogen (LMWK), and bradykinin. Kinins 
are generated from HMWK and LMWK by kininogenases such as plasma and tissue kallikrein. 
A local kallikein-kinin system exists in the heart, which enables it to synthesize and release 
kinins [34]. Kinins released locally may act as autocrine/paracrine hormones, regulating cardiac 
function. The contact activation system of the intrinsic pathway of coagulation consists of four 
plasma proteins: factor XII (FXII), factor XI (FXI), prekallikrein (PK) and HMWK. Previous 
study showed increased concentrations of FXI, HMWK and PK in patients with a history of 
myocardial infarction as compared to controls, suggesting that high PK plasma levels may favor 
contact activation resulting in increased generation of activated FXII and FXI, leading to 
enhanced activation of the intrinsic pathway of coagulation (FIX) and subsequent thrombin 
formation [35]. These data indicate that possibly due to increased cleavage of kininogen-1 in 
activated coagulation system during progression of CVD, we found decreased levels of this 
precursor. 
Lipoproteins in blood play an important physiological role transporting cholesterol, lipids 
and lipid-soluble substances to the different organs of the body. Diseases such as atherosclerosis, 
cardiovascular disease and stroke are associated with defects in lipoprotein metabolism. 
Apolipoproteins are the best lipid-related predictors to cardiovascular diseases [36]. 
Measurements of apolipoproteins are internationally standardized, automated, cost-effective and 
more convenient and precise than those for LDL cholesterol. Apolipoproteins, especially apoB, 
could also replace the standard ‘lipid profile’ as a target for therapy in at-risk patients [36]. 
Apolipoprotein B-100 (apoB) is the chief protein component constituent of the atherogenic 
very-low-density lipoprotein (VLDL), of intermediate-density lipoprotein (IDL) and of LDL 
particles, each particle including one apoB molecule [37]. ApoM is predominantly found in the 
HDL fraction and to a smaller extent in LDL, VLDL and chylomicrons. ApoM levels were 
shown to be dramatically reduced in patients with sepsis and systemic inflammatory response 
syndromes (SIRS) acting as a negative acute phase protein [38]. Apolipoprotein D (apoD) is a 
component of HDL.  
In our study, protein abundances of all 3 apolipoproteins found (apoB-100, apoM  and apoD) 
were lower in CVD group compared to healthy dogs, which was further validated by 
independent immunoassay for apoB-100 and apoD. These data were not consistent with findings 
in human medicine. Possible explanation for this is significant variations of plasma lipoprotein 
profiles among different animal species. In dogs and cats, HDL is the predominant lipoprotein 
and major cholesterol-carrying particle, with additionally quite different distribution than in 
humans. Dogs have five to six times as much HDL as LDL, whereas in humans LDL is 2 to 3 
times as much as HDL [39, 40]. In case of apoM, which has been suggested as novel negative 
acute phase protein, its decrease could be contributed to possible underlying inflammatory 
process in CVD. In affected canine valves several inflammatory cytokine genes were up-
regulated suggesting valve endothelium as a source of inflammatory mediators [24].  
To review the current status of proteomic biomarkers associated with cardiovascular diseases 
in humans, comprehensive meta-analysis was recently conducted, summarizing original research 
articles using proteomics technologies [41]. Identified proteins associated with cardiovascular 
disease represented pathways in inflammation, wound healing and coagulation, proteolysis and 
extracellular matrix organization, handling of cholesterol and LDL. Our proteomic and 
bioinformatics analysis resulted in interactome with enriched GO terms showing high 
consistency with results of this meta-analysis. Also, a prospective study in cardiovascular disease 
initiative using discovery and targeted proteomic studies, identified single protein biomarkers 
and panel of proteins that were associated with risk of myocardial infarction or atherosclerotic 
cardiovascular diseases ASCVD [31]. Two proteins from our list, tetranectin and gelsolin, were 
also highlighted as novel biomarkers of new-onset cardiovascular disease. Furthermore, another 
large study using a proteomic platform identified tetranectin as protein biomarker that predicts 
cardiovascular outcomes and all-cause mortality [42]. 
In addition to the proteomic analysis, two potential biomarkers of cardiac function in dogs 
(cTnI and NT-proBNP) were tested herein. Both cTnI and NT-proBNP were found to be 
prognostic markers for dogs with CVD at the highest risk of death [43, 44]. Cardiac troponin I is 
a protein specifically produced in the cardiomyocytes which is being rapidly released from the 
injured heart cells into the bloodstream. Since it is heart-specific, has low basal plasma 
concentration and persists in the circulation during the injury, it is commonly used as a 
biomarker of myocardial injury in humans [45]. Serum cTnI levels were found to be significantly 
increased in dogs with CVD in our study, which was already demonstrated before [46, 47]. 
Limitations of cTnI as a biomarker for CVD include its lack of specificity for the cardiac disease, 
elevation if kidney damage is present and possibly normal levels when the disease is mild [48]. 
As well as cTnI, NT-proBNP is gaining interest as a biomarker of canine heart diseases over the 
past few years. B-type natriuretic peptide (BNP) is a hormone secreted from cardiomyocytes due 
to myocardial overload and strain of the cells, in order to promote natriuresis, diuresis and 
vasodilatation. Once secreted, BNP is cleaved by serum proteases and gives rise to NT-proBNP, 
a stable biomarker of myocardium overload [49]. In several studies of dogs with CVD, there 
were increased levels of NT-proBNP compared to controls [50-52], which was also confirmed in 
our study. Nevertheless, new studies show that biologic variability should be taken into account 
when interpreting changes in both cTnI and NT-proBNP values in dogs with CVD [52, 53].   
Proteins validated with immunoassays and Western blotting showed results consistent to 
proteomics. Differences in values of fold changes between the immuno-based measurements and 
the fold changes found by proteomics could be related to the sensitivity of TMT-based LC-MS 
technology. Numerous studies have been conducted in order to compare the performance of 
immunoassays and LC-MS methodology, favoring the LC-MS in terms of accuracy and less 
false results. However, the results of those methodologies are reported as positively correlated 
[11].  As there are commercially available ELISA kits for some of the proteins listed as potential 
biomarkers for CVD, further evaluation of their prognostic value would be of interest. As 
limitations of the study, we can address limited number of cases and differences regarding sex, 
breed and age between healthy dogs and dogs with CVD. Low number of animals could be 
justified by demand for complete diagnostic investigation, while inadequate crossmatching is 
also a result of disease occurring in dogs at an advanced age.  
5. Conclusions 
Label-based high-resolution quantitative proteomics analysis and bioinformatics approach 
used herein represent a valid tool for elucidating complex pathophysiology of canine CVD and 
unveiling disease relevant proteins with biomarker potential. Early diagnosis and therapeutic 
intervention may prevent severe complications in dogs with CVD. Therefore, it is crucial to 
identify biomarkers that can be used in clinical practice. We found comparative similarities with 
human disease in terms of identified proteins and GO pathways, which confirmed similar 
pathophysiology of this disease, but also differences, mainly in lipid metabolism. Proteins 
associated with extracellular structure organization, haemostasis pathway and lipoprotein 
metabolism were identified as potential markers in canine CVD. 
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 Figure legends 
 
Figure 1. In silico inferred interactome network of identified GO terms over-represented in 
canine CVD (healthy versus dogs with CVD). Differentially expressed proteins interacting with 
at least 1 term were added. Radial layout was applied and the GO group leader terms are in black 
text.  
 
Figure 2. Concentrations of adiponectin (ADPN), apolipoprotein B-100 and apolipoprotein D in 
serum of dogs with CVD and healthy dogs in a box and whisker plot (median is marked with a 
vertical line inside the box, the box spans the interquartile range, whiskers min-max). 
 
Figure 3. Western blotting and relative density comparison of serum adiponectin from healthy 
dogs and dogs with CVD (figures of individual membranes were cropped to show the band of 
interest; data are shown as median with range, P = 0.005). 
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